Digital Diagnostics is at the forefront of healthcare innovation with its flagship product, LumineticsCore™, an autonomous AI diagnostic system designed to detect diabetic retinopathy, including macular edema, at the point-of-care. This FDA-cleared technology allows healthcare providers to capture images of patients' retinas using a fundus camera, which are then analyzed by LumineticsCore™ to deliver diagnostic results in under a minute. The system is designed to improve patient access to specialty care by providing immediate results, thereby facilitating timely referrals to eye care professionals when necessary. By closing the care gap for diabetic eye exams, LumineticsCore™ enhances the quality of diabetes management and has been shown to significantly increase adherence rates for annual eye exams.

In addition to its primary function, Digital Diagnostics is actively exploring the potential of AI in diagnosing other conditions, such as glaucoma, age-related macular degeneration (AMD), and cardiovascular issues, by leveraging fundus imaging. The company emphasizes a patient outcomes-driven approach, focusing on accessibility, affordability, and equity in healthcare. With a commitment to ethical AI development, LumineticsCore™ has been rigorously validated against patient outcomes, ensuring that it works effectively across diverse populations. This innovative technology not only aims to prevent vision loss but also seeks to revolutionize the standards of care in diabetes management and beyond.

United States

Digital Diagnostics is an Iowa-based AI diagnostic platform that offers solutions such as image analysis and EMR integration for the healthcare industry.

Digital Diagnostics

Company Details